Infusion Reaction Acute Event Note

Date/Time of Event: [Date and time of symptom onset]
Date/Time Documented: [Date and time of documentation]
Location: [Infusion center / clinic / hospital unit], [chair/bed number], [service line]
Author/Role: [Name, credentials, role]

Event Summary

[2–5 sentence synopsis including: triggering infusion agent and cycle/day if applicable; timing relative to infusion start or rate escalation; key symptoms with airway, breathing, and circulation features explicitly stated as present or absent; key interventions performed; immediate outcome and disposition; plan for future infusions] (If any element is pending, state "pending [responsible party] by [timeframe]." Do not use bullet points.)

Clinical Details

Medication/Biologic and Indication: [Agent name and formulation] — [Indication/diagnosis]

Ordered Dose and Planned Rate: [Total dose, concentration, planned infusion rate/schedule including rate-escalation steps if applicable]

Premedications and Times: [Premedications with dose, route, and time relative to infusion start]

Infusion Start Time: [Time]
Rate at Onset of Symptoms: [Rate and escalation step if applicable]

Prior Exposure/Reactions: [Naïve / previously exposed with number of prior doses]; [Prior reactions with description and grade / none known / not documented]

Patient-Reported Symptoms: [Onset pattern, time from infusion start, progression, primary symptoms] (If timing uncertain, state "time approximate.")

Observed Signs by System:

• Airway: [Findings or normal / not assessed]
• Breathing: [Findings including SpO2 or normal / not assessed]
• Circulation: [Findings including BP, HR or normal / not assessed]
• Skin: [Findings or normal / not assessed]
• Other Pertinent Systems: [GI, neurologic, or other findings / not assessed]

(Explicitly state presence or absence for high-stakes systems. If not assessed, document "not assessed.")

Vital Signs:

Time	BP	HR	RR	SpO2	O2 Delivery
Baseline (pre-infusion): [time]	[BP]	[HR]	[RR]	[SpO2]	[Room air / supplemental O2]
Symptom onset: [time]	[BP]	[HR]	[RR]	[SpO2]	[O2 delivery]
After intervention(s): [time]	[BP]	[HR]	[RR]	[SpO2]	[O2 delivery]
Resolution/Transfer: [time]	[BP]	[HR]	[RR]	[SpO2]	[O2 delivery]

(If continuous monitoring used, summarize trend and nadir/peak values. If vital sign not documented, state "not documented.")

Management Timeline

(Provide timestamped entries in chronological order. Use exact times when available; if uncertain, state "approximate.")

• [Time] — Symptom onset: [symptoms noted]
• [Time] — Infusion [paused / stopped] at rate [rate]
• [Time] — [Medication, dose, route] given for [indication]; response: [improved / no change / worsened]
• [Time] — [Fluids: type, volume, rate] (if applicable)
• [Time] — Oxygen [initiated / escalated] to [device, flow rate]; response: [SpO2 change] (if applicable)
• [Time] — Rapid response [activated / not activated with rationale] (if applicable)
• [Time] — [Medication] intentionally not given; rationale: [clinical reasoning] (if applicable)
• [Time] — Infusion restarted at [rate]; tolerance: [tolerated / not tolerated] (if applicable)
• [Time] — Disposition: [continue observation / discharge / transfer to location]

Assessment

Severity Classification: [CTCAE infusion-related reaction / institutional protocol] — Grade [1 / 2 / 3 / 4]
Justification: [Specific criteria met] (Do not assign grade without citing criteria.)

Suspected Causative Agent: [Agent name] — [definite / probable / possible / unlikely]
Suspected Mechanism: [Infusion reaction / hypersensitivity / cytokine release–like / unclear] (If uncertain, use "suspected infusion reaction" rather than declaring IgE-mediated.)

Differential Considerations: [Competing explanations considered with supporting or refuting features, or "none—reaction pattern classic for infusion reaction"]

Plan

Disposition: [Observation duration / discharge with return precautions / transfer to ED, ICU, or other]; biphasic recurrence education: [provided / not provided]

Future Infusion Plan: [Continue as scheduled / hold pending review / resume with modifications] (Include premedication changes, rate reduction, extended infusion, enhanced monitoring, higher-acuity setting, alternative agent, or desensitization as applicable. If undetermined, state: "Future infusion plan to be determined—[service] to review before next scheduled dose on [date].")

Allergy/Adverse Reaction List Update: [Agent name, reaction phenotype, severity/grade, date, rechallenge status] (If pending, state "pending [responsible party].")

Notifications: [Ordering provider, pharmacy, safety event report, clinical trial sponsor as applicable with times or "pending"]

(For missing high-safety elements—onset time, vital signs, epinephrine use, disposition—state "not documented" rather than omitting.)